What is Generalized Anxiety Disorder?
Anxiety disorders are characterized by uncontrollable worry about daily events in a person’s life. The different kinds of anxiety include generalized anxiety disorder, panic disorder, specific phobias, agoraphobia, social anxiety disorder and separation anxiety disorder.
Generalized anxiety disorder (GAD) includes certain symptoms such as headache, tension, profuse sweating and tiredness. It has been observed that GAD occurs along with other anxiety disorder and depression. A large number of factors are responsible for the occurrence of GAD such as genetics, brain chemistry, and exposure to stressful event, family background, or life experiences.
This report incorporates an in-depth assessment of generalized anxiety disorder market by therapeutics type, therapies, devices and geography.
Market Research and Market Trends of Generalized Anxiety Disorder:
Fisher Wallace Simulator, an FDA-approved neurostimulation device to help treat depression, anxiety and insomnia. It is headband like device which stimulates the brain to release certain hormones such as dopamine which is known to reduce stress. Fisher Wallace Stimulator makes it possible to sit at home and engage in neurostimulation therapy. This can help patients to be naturally treated with the same effect as that of an antidepressant.
Scientists are currently working on finding the biomarkers that will categorize anxiety disorders more accurately. This data would help to understand the response of each drug to a particular disorder and thus could help to push therapeutic research forward driving the market during the forecast period.
Aloradine, a nasal spray-delivered agent, has a novel mechanism of action that stimulates nasal chemoreceptors. This transmits messages rapidly to the brain’s limbic system, amygdala and hypothalamus directly modulating brain autonomic, psychophysiological, and neuroendocrine responses and reducing stress and anxiety. This drug can be self-administered using a simple, low-cost device.
Currently, there is a lot of research going on to qualify a probiotic as a psychobiotic which would specifically provide mental health benefits. The effect of psychobiotic in the intestine would be conveyed to the brain and the other organs by the vagus nerve which is known to have a link between the nervous system and the digestive system.
Who are the Major Players in Generalized Anxiety Disorder market?
The companies referred to in the market research report include GlaxoSmithKline Pharmaceuticals Limited, Bristol-Myers Squibb, Sumitomo Dainippon Pharma, Noven Pharmaceuticals, Inc., Actavis Pharmaceutical Company, F. Hoffmann-La Roche, Abbott Laboratories, Eli Lilly and Company, Pfizer Inc., Shionogi and Company
What is our report scope?
The report incorporates in-depth assessment the competitive landscape, product market sizing, product benchmarking, market trends, product developments, financial analysis, strategic analysis so on to gauge the impact forces potential opportunities the market. Apart from this the report also includes a study major developments in the market such as product launches, agreements, acquisitions, collaborations, mergers so on to comprehend the prevailing market dynamics at present its impact during the forecast period 2018-2024.
Key Takeaways from this Report
- Evaluate market potential through analyzing growth rates (CAGR %), Volume (Units) Value ($M) data given at country level – for product types, end use applications by different industry verticals.
- Underset the different dynamics influencing the market – key driving factors, challenges hidden opportunities.
- Get in-depth insights on your competitor performance – market shares, strategies, financial benchmarking, product benchmarking, SWOT more.
- Analyze the sales distribution channels across key geographies to improve top-line revenues.
- Underset the industry supply chain with a deep-dive on the value augmentation at each step, in order to optimize value bring efficiencies in your processes.
- Get a quick outlook on the market entropy – M&A’s, deals, partnerships, and product launches all key players for the past 4 years.
- Evaluate the supply-dem gaps, import-export statistics regulatory lscape for more than top 20 countries globally for the market.
This report will be delivered within 2 business days.
1.1. Definitions and Scope
2. Generalized Anxiety Disorder Market - Executive summary
2.1. Market Revenue, Market Size and Key Trends by Company
2.2. Key Trends by type of Application
2.3. Key Trends segmented by Geography
3. Generalized Anxiety Disorder Market
3.1. Comparative analysis
3.1.1. Product Benchmarking - Top 10 companies
3.1.2. Top 5 Financials Analysis
3.1.3. Market Value split by Top 10 companies
3.1.4. Patent Analysis - Top 10 companies
3.1.5. Pricing Analysis
4. Generalized Anxiety Disorder Market Forces
4.4. Porters five force model
4.4.1. Bargaining power of suppliers
4.4.2. Bargaining powers of customers
4.4.3. Threat of new entrants
4.4.4. Rivalry among existing players
4.4.5. Threat of substitutes
5. Generalized Anxiety Disorder Market -Strategic analysis
5.1. Value chain analysis
5.2. Opportunities analysis
5.3. Product life cycle
5.4. Suppliers and distributors Market Share
6. Generalized Anxiety Disorder Market – By Therapeutics Type (Market Size -$Million / $Billion)
6.1. Market Size and Market Share Analysis
6.2. Application Revenue and Trend Research
6.3. Product Segment Analysis
184.108.40.206. Selective serotonin reuptake inhibitor (SSRI)
220.127.116.11. Serotonin norepinephrine reuptake inhibitor (SNRI)
18.104.22.168. Tricyclic antidepressant (TCA)
22.214.171.124. Monoamine Oxidase Inhibitors (MAOIs)
126.96.36.199.6. Others (Buspirone)
7. Generalized Anxiety Disorder Market – by Therapies type (Market Size -$Million / $Billion)
7.1. Interpersonal Therapy (IPT)
7.2. Behaviour Therapy
7.3. Cognitive Behavioral Therapy (CBT)
7.4. Mindfulness-based Cognitive Therapy (MBCT)
8. Generalized Anxiety Disorder Market – by Medical devices type (Market Size -$Million / $Billion)
8.1. Deep Brain Stimulation (DBS)
8.2. Electroconvulsive Therapy (ECT)
8.3. Trans cranial Magnetic Stimulation (TMS)
8.4. Vagus Nerve Stimulation (VNS)
9. Generalized Anxiety Disorder - By Geography (Market Size -$Million / $Billion)
9.1. Generalized Anxiety Disorder Market - North America Segment Research
9.2. North America Market Research (Million / $Billion)
9.2.1. Segment type Size and Market Size Analysis
9.2.2. Revenue and Trends
9.2.3. Application Revenue and Trends by type of Application
9.2.4. Company Revenue and Product Analysis
9.2.5. North America Product type and Application Market Size
188.8.131.52. Rest of North America
9.3. Generalized Anxiety Disorder - South America Segment Research
9.4. South America Market Research (Market Size -$Million / $Billion)
9.4.1. Segment type Size and Market Size Analysis
9.4.2. Revenue and Trends
9.4.3. Application Revenue and Trends by type of Application
9.4.4. Company Revenue and Product Analysis
9.4.5. South America Product type and Application Market Size
184.108.40.206. Costa Rica
220.127.116.11. Rest of South America
9.5. Generalized Anxiety Disorder - Europe Segment Research
9.6. Europe Market Research (Market Size -$Million / $Billion)
9.6.1. Segment type Size and Market Size Analysis
9.6.2. Revenue and Trends
9.6.3. Application Revenue and Trends by type of Application
9.6.4. Company Revenue and Product Analysis
9.6.5. Europe Segment Product type and Application Market Size
18.104.22.168. Rest of Europe
9.7. Generalized Anxiety Disorder – APAC Segment Research
9.8. APAC Market Research (Market Size -$Million / $Billion)
9.8.1. Segment type Size and Market Size Analysis
9.8.2. Revenue and Trends
9.8.3. Application Revenue and Trends by type of Application
9.8.4. Company Revenue and Product Analysis
9.8.5. APAC Segment – Product type and Application Market Size
22.214.171.124. South Korea
10. Generalized Anxiety Disorder Market - Entropy
10.1. New product launches
10.2. M&A's, collaborations, JVs and partnerships
11. Generalized Anxiety Disorder Market Company Analysis
11.1. Market Share, Company Revenue, Products, M&A, Developments
11.2. GlaxoSmithKline Pharmaceuticals Limited
11.3. Bristol-Myers Squibb
11.4. Sumitomo Dainippon Pharma
11.5. Noven Pharmaceuticals, Inc.
11.6. Actavis Pharmaceutical Company
11.7. F. Hoffmann-La Roche
11.8. Abbott Laboratories
11.9. Eli Lilly and Company
11.10. Pfizer Inc.
11.11. Shionogi and Company
12. Generalized Anxiety Disorder Market -Appendix